- Home
- RBBN vs XERS Comparison
RBBN vs XERS Comparison
Compare RBBN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBBN
- XERS
- Stock Information
- Founded
- RBBN 1997
- XERS 2005
- Country
- RBBN United States
- XERS United States
- Employees
- RBBN N/A
- XERS N/A
- Industry
- RBBN EDP Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- RBBN Technology
- XERS Health Care
- Exchange
- RBBN Nasdaq
- XERS Nasdaq
- Market Cap
- RBBN 671.1M
- XERS 752.7M
- IPO Year
- RBBN 2000
- XERS 2018
- Fundamental
- Price
- RBBN $3.97
- XERS $7.75
- Analyst Decision
- RBBN Strong Buy
- XERS Strong Buy
- Analyst Count
- RBBN 4
- XERS 7
- Target Price
- RBBN $6.00
- XERS $6.79
- AVG Volume (30 Days)
- RBBN 504.8K
- XERS 3.4M
- Earning Date
- RBBN 07-23-2025
- XERS 08-07-2025
- Dividend Yield
- RBBN N/A
- XERS N/A
- EPS Growth
- RBBN N/A
- XERS N/A
- EPS
- RBBN N/A
- XERS N/A
- Revenue
- RBBN $863,459,000.00
- XERS $246,025,000.00
- Revenue This Year
- RBBN $7.26
- XERS $35.31
- Revenue Next Year
- RBBN $5.52
- XERS $19.65
- P/E Ratio
- RBBN N/A
- XERS N/A
- Revenue Growth
- RBBN 7.68
- XERS 35.62
- 52 Week Low
- RBBN $2.84
- XERS $2.48
- 52 Week High
- RBBN $5.38
- XERS $7.79
- Technical
- Relative Strength Index (RSI)
- RBBN 54.43
- XERS 80.09
- Support Level
- RBBN $3.63
- XERS $7.27
- Resistance Level
- RBBN $3.85
- XERS $7.79
- Average True Range (ATR)
- RBBN 0.15
- XERS 0.41
- MACD
- RBBN 0.00
- XERS 0.08
- Stochastic Oscillator
- RBBN 74.07
- XERS 98.43
About RBBN Ribbon Communications Inc.
Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).